Literature DB >> 971716

Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.

C J van Boxtel, J T Wilson, S Lindgren, F Sjöqvist.   

Abstract

A previously described GLC method has been modified and applied to measurement of antipyrine levels in plasma, blood and saliva of man following administration of a single oral dose (10 mg/kg). Tery time studied. The half-life of antipyrine determined in blood, plasma or saliva in any given individual was similar. The intersubject variation in half-life was about two-fold (n = 5). Antipyrine levels in saliva were not affected by the rate of saliva flow when collections were made continuously for 20 minutes. This study has demonstrated that kinetic data about antipyrine comparable to that from plasma may also be obtained from readily accessible tissue fluids, such as saliva and capillary blood.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971716     DOI: 10.1007/BF00561668

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  The use of antipyrine in the measurement of total body water in man.

Authors:  R SOBERMAN; B B BRODIE
Journal:  J Biol Chem       Date:  1949-05       Impact factor: 5.157

2.  Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers.

Authors:  S Lindgren; P Collste; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

3.  Indirect plasma-theophylline monitoring in asthmatic children by determination of theophylline concentration in saliva.

Authors:  G Levy; E F Ellis; R Koysooko
Journal:  Pediatrics       Date:  1974-06       Impact factor: 7.124

4.  Relationship between theophylline concentration in plasma and saliva of man.

Authors:  R Koysooko; E F Ellis; G Levy
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

5.  GLC determination of theophylline in biological fluids.

Authors:  V P Shah; S Riegelman
Journal:  J Pharm Sci       Date:  1974-08       Impact factor: 3.534

6.  Impairment of drug metabolism by disulfiram in man.

Authors:  E S Vesell; G T Passananti; C H Lee
Journal:  Clin Pharmacol Ther       Date:  1971 Sep-Oct       Impact factor: 6.875

7.  Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides.

Authors:  B Kolmodin; D L Azarnoff; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1969 Sep-Oct       Impact factor: 6.875

8.  Salivary excretion of paracetamol in man.

Authors:  J P Glynn; W Bastain
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765

9.  Digoxin concentrations in serum and saliva.

Authors:  W J Jusko; L Gerbracht; L H Golden; J R Koup
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1975-01

10.  Application of salivary salicylate data to biopharmaceutical studies of salicylates.

Authors:  G Graham; M Rowland
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

View more
  14 in total

1.  Simplified determination of antipyrine clearance by liquid chromatography of a microsample of saliva or plasma.

Authors:  A el-Yazigi; D A Raines; H Ali; J Sieck; P Ernst; M Dossing
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

2.  Rectal motility and bioavailability.

Authors:  J J Tukker; C J de Blaey; G A Charbon
Journal:  Pharm Res       Date:  1984-07       Impact factor: 4.200

Review 3.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

4.  Effect of vitamin C supplement on antipyrine disposition in man.

Authors:  J B Houston
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

5.  Ethical considerations in the conduct of clinical pharmacokinetic studies.

Authors:  C K Svensson
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

6.  Lack of hepatic enzyme inducing effect of sodium valproate.

Authors:  J Oxley; A Hedges; K A Makki; A Monks; A Richens
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

7.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

8.  Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.

Authors:  M Danhof; A van Zuilen; J K Boeijinga; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.

Authors:  J Posner; M Danhof; M W Teunissen; D D Breimer; P D Whiteman
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

10.  A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.

Authors:  E Perucca; A Hedges; K A Makki; M Ruprah; J F Wilson; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.